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Abstract
Background: Human leukocyte antigen (HLA)-class I molecules on tumor cells have been regarded as crucial sites
where cytotoxic T lymphocytes (CTL) can recognize tumor-specific antigens and are strongly associated with anti-
tumor activity. However, the clinical impact of HLA class I expression in breast cancer has not been clarified.
Methods: A total of 212 breast cancer patients who received curative surgery from 1993 to 2003 were enrolled in
the current study. HLA class I expression was examined immunohistochemically using an anti-HLA class I
monoclonal antibody. The correlation between HLA class I positivity and clinical factors was analyzed.
Results: The downregulation of HLA class I expression in breast cancer was observed in 69 patients (32.5%). HLA
class I downregulation was significantly associated with nodal involvement (p < 0.05), TNM stage (p < 0.05),
lymphatic invasion (p < 0.01), and venous invasion (p < 0.05). Patients with preserved HLA class I had significantly
better disease-free interval (DFI) than those with loss of HLA class I (p < 0.05). However, in multivariable analysis,
HLA class I was not selected as one of the independent prognostic factors of disease-free interval.
Conclusion: The examination of HLA class I expression is useful for the prediction of tumor progression and
recurrent risk of breast cancer via the antitumor immune system.
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Background
The antitumor activity via cytotoxic T lymphocytes (CTL)
or tumor antigen has been clarified in the oncological field.
Activation of anti-tumor CTL requires the recognition of
immunogenic epitopes presented on various types of
human leukocyte antigen (HLA) class I molecules on the
tumor [1-4]. The concept of immune surveillance is main-
taining the relationship between tumor-associated antigens
(TAA) complexing with the HLA class I and tumor-specific
cytotoxic T cells. These activated tumor-specific cytotoxic
T cells can eliminate cancer cells specifically. The loss of
HLA class I on the tumor is believed to lead to malfunction
of recognition by the CD8+ T cells. It is already known that
malignancies exhibit altered or lost expression of histocom-
patible antigens on the tumor cells [5-7]. Loss of HLA class
I antigens appears to be a significant mechanism by which
tumor cells escape specific immune attack and causes pro-
blems in the design of antitumor immunotherapy [7]. The
loss of HLA class I antigens on tumor cells has been
reported in several human tumors [5-7], and the loss of
HLA class I molecules has been discussed in the context of
tumor aggressiveness, such as differentiation of histology
[8-10], invasiveness, and metastatic potential [5,11].
The non-covalent association with b 2-microglobulin (b
2 m) is essential for the structural stability and optimal
function of HLA class I molecules [12]. Thus, several
authors have used immunostaining of b 2 m for the analy-
sis of overall surface expression of HLA class I molecules
[9,11,13]. However, there are often difficulties in evaluating
immunostaining using anti-MHC class I monoclonal anti-
bodies (mAbs), such as W6/32, HC-10, or HC-A2, as
these type of antibodies are not ideal for the immunostain-
ing of formalin-fixed, paraffin-embedded tissue. Moreover,
these antibodies are not fully recognized whole HLA class
I properly. Recently, EMR8-5, a monoclonal antibody
against HLA class I heavy chains (HLA-A, B, C), has been
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validated in HLA class I immunohistochemistry [14-16],
and used to investigate HLA class I expression in osteosar-
coma [14], non-small cell lung cancer [15], and renal cell
carcinoma [16]. The clinical implication of the HLA class I
expression has been discussed and reviewed in breast can-
cer and it is not clarified [17-21]. Moreover, there have
been no studies on HLA class I expression of breast cancer
by EMR8-5. The present study assessed HLA class I
expression in invasive breast cancer by immunohisto-
chemistry using the EMR8-5 antibody, analyzed associa-
tions with clinicopathological factors, and discussed the
clinical implication of HLA class I-positive breast cancer.
Methods
Patients
A total of 212 breast cancer patients, who consecutively
underwent curative operation for primary invasive breast
cancer at Kagoshima University Hospital from 1993 and
2003, were enrolled in the current study. None of the
patients received any preoperative systemic chemother-
apy or endocrine therapy. Clinicopathological features
were documented according to TNM classification [17].
All patients were female and their mean age was 56 (ran-
ging from age 23 to 90). One hundred and fifty-three
underwent mastectomy and the remaining 59 underwent
partial resection. A total of 84 patients had nodal involve-
ment, and the numbers of patients with stages I, II, and
III were 70, 101, and 41, respectively. This study was
approved by the Ethical Committee of the University of
Kagoshima, and written informed consent was obtained
from all individuals. Overexpression of the estrogen
receptor (ER), progesterone receptor (PgR), and HER2
were examined by immunohistochemical staining using
the appropriate primary antibodies. Distinct staining of
the nucleus in more than 10% of tumor cells was
recorded as positive for ER and PgR, and strong mem-
brane staining in more than 10% of invasive lesions was
recorded as positive for HER2.
Immunohistochemical analysis of HLA class I in breast
cancer
HLA class I expression was investigated by immunohisto-
chemical staining with the monoclonal anti-pan HLA-
class I antibody 5 EMR8-5 (Cosmo Bio Co., Tokyo, Japan).
EMR8-5 is an anti-pan HLA class I monoclonal antibody,
which can recognize all of HLA A, B, and C heavy chain
even in formalin-fixed tissue [22].
The avidin-biotin complex (ABC) method was used to
visualize HLA class I expression in breast cancer. Human
tonsil sections were used as positive controls for HLA
class I, and in the negative controls, the primary antibody
was replaced with buffer. The ABC method was performed
in accordance with previous reports [14-16]. Namely,
4 μm paraffin-embedded sections of breast cancer were
de-paraffinized and soaked in PBS. The sections were
treated with 3% H2O2 for 30 min in order to block endo-
genous tissue peroxidases, followed by treatment with rab-
bit serum for 60 min in order to reduce non-specific
binding. Primary anti-HLA-class I antibody was diluted to
1:100 and incubated with the tonsil sections at 4°C over-
night. Sections were rinsed in PBS and visualized using
standard techniques for labeled avidin-biotin immunoper-
oxidase staining.
All specimens were reviewed independently using light
microscopy for at least five areas at a 400 × magnification
by two investigators (KK and SI) who were blinded with
respect to the clinicopathological data. The intensity of
HLA-class I staining was evaluated in accordance with a
previous report [23], using the following criteria: strongly
positive (positive), defined as complete membrane stain-
ing in 40% or more of tumor cells; weakly positive (nega-
tive), any lesser degree of staining appreciable in tumor
cells; and absent (negative), no appreciable staining in
tumor cells.
Survival analysis and statistical evaluation
Postoperative intervals were estimated by the Kaplan-
Meier method. In the survival analysis, we excluded the
cases that had not undergone curative resection. The end-
point of survival analysis was defined as the day of death
of each patient from not only cancer-related events but
also other causes. That of disease-free survival (DFS) was
defined as a locoregional recurrence or distant metastasis
of breast cancer in soft tissue, lymph nodes, liver, lung,
brain, and/or bone by physical and/or pathological exami-
nation. Overall survival (OS) and DFS of 212 patients were
88.4% and 83.0%, respectively. Median and mean survivals
of these patients were 71.9 and 76.2 months, respectively.
Significant differences of DFS and OS were calculated
using the log-rank test, and significant differences in
categorical variables were analyzed by the c2-test. Uni-
variate and multivariable analyses of the postoperative
outcome were conducted using Cox’s proportional
hazards model. Differences were considered significant at
p < 0.05. All statistical analyses were performed using
Stat View 5.0 software.
Results
Expression and evaluation of HLA class I in breast cancer
tissue
HLA class I positivity was found in not only the mem-
brane of tumor cells but also in the cytoplasm of tumor
cells (Figure 1). In addition, Some stromal lymphocytes
also showed HLA class I positivity. Generally, there was
little HLA class I positivity in normal mammary glands
adjacent to cancerous tissue. According to the previously
mentioned evaluation, 69 patients (32.5%) had strong
HLA class I expression, 64 patients (30.2%) had weak
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expression, and the remaining 79 patients (37.3%) lacked
expression. Patients with weak or no expression of HLA
class I antigens in breast cancer were classified as the
downregulated HLA class I group. In contrast, patients
with more than 40% of HLA class I positivity were classi-
fied as the positive HLA class I group.
Association between HLA class I and clinicopathological
factors
The downregulation of HLA class I expression in breast
cancer was significantly associated with nodal metastasis,
TNM, lymphatic invasion, and venous invasion (p = 0.04,
p = 0.01, p = 0.006, and p = 0.04, respectively) (Table 1).
There was no significant association between HLA class I
expression and histology or hormonal status.
Patients’ overall survival (OS) and disease-free survival
(DFS) with or without HLA class I expression in breast
cancer
Postoperative OS was not significantly different accord-
ing to HLA class I expression. However, patients with
HLA class I positivity had significantly longer DFS than
those without HLA class I positivity (p < 0.05) (Figure 2).
Using univariate analysis, seven clinical factors, including
HLA class I expression, were selected as significant for
DFS (Table 2). According to multivariable analysis using
these seven factors, lymph node metastasis, progesterone
receptor, and vascular invasion were independent prog-
nostic factors. HLA class I expression was not selected as
an independent factor for DFS (Table 2).
Discussion
The monoclonal antibody EMR8-5 can recognize all of
HLA A, B, and C heavy chain even in formalin-fixed tis-
sue. In this context, EMR8-5 can recognize whole HLA
molecules, and its validity was supported by the immu-
nostaining performed in our current studies. Cordon et
al. reported that HLA class I positivity examined using
the conventional HLA class I antibody W6/32, which
also recognizes all HLA class I antigens, was 30% of HLA
class I positivity in breast cancer, similar to that shown in
our present study [24]. In contrast, Madjd et al. investi-
gated HLA class I expression in breast cancer using a
HC-10 antibody [24], and demonstrated that HLA class I
negativity correlated with a better postoperative outcome.
These results conflicted with the data in our studies. This
discrepancy may be explained by the fact that whereas
the HC10 mAb scarcely reacts with HLA-A alleles, the
anti- HLA class I heavy chain mAb EMR8-5 can detect
all recombinant proteins of HLA-A, B, and C alleles by
immunoblot analysis [25]. In addition, EMR8-5 can be
applied to paraffin-fixed specimens, so in this context it
is an ideal antibody for evaluating cancerous HLA class I
antigen expression.
In our current study, the downregulation of HLA class I
expression in breast cancer was 66%, which was more
than that in gastric (32%) [22] and esophageal cancer
(43%) [26], and osteosarcoma (55%) [14], but less than the
downregulation in lung cancer (70%) [15]. The degree of
HLA class I loss may be affected by organ specificity. For
example, Ishigami et al. speculated that highly preserved
HLA class I expression in gastric cancer is partly due to
exogenous stimulation from gastritis or bacterial infection
of Helicobacter pylori [22]. The differences in HLA class I
expression in breast cancer may also be explained by the
possible inflammation and proteolysis that can occur at
the sites of breast cancer origin. These are important steps
linked both to HLA loss and cancer aggressiveness. In this
study, there was little HLA class I positivity in normal
A
(Original magnification, x400)(Original magnification, x400)
B
Figure 1 Representative images of immunostaining of HLA class I in invasive breast cancer. A: positive expression, B: downregulated
expression.
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mammary gland tissue. In contrast, HLA class I antigens
were preserved in early breast cancer, and cancerous HLA
class I antigens were newly expressed or reduced accord-
ing to the tumor extension. Although T1 tumors had 41%
HLA class I positivity, T3-4 tumors only showed 15% posi-
tivity. According to tumor extension, preservation of HLA
class I of the tumor was reduced. This clinical trait was
also reported in other types of malignancies, such as gas-
trointestinal cancer [22,26] and sarcoma [14]. It is possible
that, in the process of tumor extension, tumors that lost
HLA class I survived and escaped from antigen-specific
CTL-mediated lysis leading to tumor dissemination and
metastasis. However, these results do not fully explain the
relationship with metastasis, therefore we need to perform
more analyses comparing the results among in situ, lobu-
lar and ductal breast cancers on key parameters, such as
VEGF, MMP etc.
In the current study, the downregulation of HLA class I
expression was significantly associated with lymphatic
and nodal invasion. Mizukami et al. showed that when
HLA class I-positive esophageal cancer metastasized to
the lymph node, tumor cells completely lost HLA class I
expression in this system [22]. Zia et al. investigated the
immunological characteristics of isolated cancer cells
(ITC) in bone marrow and found that ITCs with the
HLA class I downregulation phenotype were often
derived from poorly differentiated primary breast carci-
nomas which was associated with a short survival period
in breast cancer [27]. Therefore, cancerous HLA class I
downregulation seems to be conducive to metastasis to
other organs.
Patients with positive HLA class I expression showed a
better DFS in comparison with those with downregulation
of HLA class I expression. This result differs from that for
Table 1 Association between clinical factors and HLA class I expression in 212 breast cancer patients
Positive (n = 69) Negative (n = 143) p value
Age (years)
< 50 23 (11%) 59 (28%) 0.2669
51 < 46 (22%) 84 (40%)
Tumor size
T1 35 (17%) 51 (24%) 0.0641
T2 31 (15%) 72 (34%)
T3 1 12 (57%)
T4 2 8 (4%)
Nodal invasion
Negative 49 (23%) 79 (37%) 0.0278
Positive 20 (9%) 64 (30%)
Estrogen receptor
Negative 18 (8%) 53 (25%) 0.1126
Positive 51 (24%) 90 (42%)
Progesterone receptor
Negative 25 (12%) 64 (30%) 0.2387
Positive 44 (21%) 79 (37%)
Lymphatic invasion
Negative 46 (22%) 67 (32%) 0.0067
Positive 23 (11%) 76 (36%)
Venous invation
Negative 66 (31%) 122 (58%) 0.0260
Positive 3 (1%) 21 (10%)
TNM
I 31 (15%) 39 (18%) 0.0110
II 31 (15%) 70 (33%)
III 7 (3%) 34 (16%)
Histology
IDC 67 (32%) 142 (67%) 0.2040
ILC 2 1
HER2 receptor
Negative 63 (30%) 123 (58%) 0.4539
Positive 6 (3%) 17 (8%)
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esophageal cancer [26]. In breast cancer, the average OS is
generally better than those in other malignancies; DFS is
often used to evaluate aggressiveness of biological markers
in breast cancer. In this context, significant differentiation
in DFS seems to be meaningful.
It has been clarified that HLA molecule inactivity
depends not only on the expression of HLA class I
molecules themselves, but also on the post-transcrip-
tional course that mainly affects b2-microglobulin gene
expression. Aptsiauri et al. [28] showed that if apparent
tumor cells expressed HLA class I, various types of HLA
class I alterations were found in malignancies and in the
molecular mechanisms that underlie these defects. In
this context, the HLA class I molecules preserved in
these breast cancers may exhibit altered expression and
dysfunction as antigen presentation molecules. It seems
to be difficult to precisely evaluate HLA class I expres-
sion, however, in the current study, we evaluate HLA
expression including in b2 microglobulin expression
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Figure 2 Disease free survival according to HLA class I expression. Surgical outcome of the HLA class I positive group was significantly
better than that of the downregulated group (p < 0.05).
Table 2 Univariate and multivariable analyses for DFS
Univariate analysis Multivariable analysis
Disease free interval Disease free interval
Variables Categories HR (95% confidence interval) p value HR (95% confidence interval) p value
Tumor size T3+T4 (vs T1+T2) 0.249 (0.120 - 0.514) P = 0.0020 0.459 (0.212 - 0.995) P = 0.0485
Nodal involvement N1 (vs N0) 0.148 (0.068 - 0.324) P < 0.0001 0.230 (0.092 - 0.574) P = 0.0016
Estrogen receptor Positive (vs negative) 1.656 (0.872 - 3.146) 0.1231
Progesterone receptor Positive (vs negative) 1.932 (1.019 - 3.664) P = 0.0437 2.168 (1.109 - 4.240) P = 0.0237
Lymphatic invasion Positive (vs negative) 0.246 (0.117 - 0.521) P = 0.0020 0.871 (0.346 - 2.194) 0.7689
Vascular invasion Positive (vs negative) 0.184 (0.094 - 0.361) P < 0.0001 0.423 (0.198 - 0.904) P = 0.0264
HER2 receptor Positive (vs negative) 0.653 (0.272 - 1.565) 0.3390
HLA class I expression Negative (vs positive) 2.513 (1.050 - 6.012) P = 0.0384 1.691 (0.696 - 4.110) 0.2462
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Conclusions
The downregulation of HLA class I expression fre-
quently occurred in breast cancer, in a similar manner
to what has been seen in several other cancers, and it
may also be associated with tumor progression and
relapse. Therefore HLA class I status may be useful with
other well-known prognostic factors like nodal involve-
ment and hormone status to evaluate postoperative out-
comes in breast cancer.
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